I. Hollander

发表

Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors.

N. Brooijmans, L. Toral-Barza, K. Curran, 2009, Journal of medicinal chemistry.

Scalarane-based sesterterpenoid RCE-protease inhibitors isolated from the Indonesian marine sponge Carteriospongia foliascens.

David E. Williams, R. Andersen, L. Feldberg, 2009, Journal of natural products.

ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.

R. Abraham, N. Brooijmans, J. Gibbons, 2009, Journal of medicinal chemistry.

Determination of the loading values for high levels of drugs and sugars conjugated to proteins by matrix‐assisted ultraviolet laser desorption/ionization mass spectrometry

M. Karas, A. Wissner, F. Hillenkamp, 1993 .

4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).

N. Brooijmans, N. Zhang, L. Toral-Barza, 2010, Bioorganic & medicinal chemistry letters.

Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).

N. Brooijmans, L. Toral-Barza, J. Bard, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).

N. Brooijmans, L. Toral-Barza, A. Zask, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.

L. Toral-Barza, J. Lucas, K. Curran, 2010, Bioorganic & medicinal chemistry letters.

Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.

L. Toral-Barza, J. Lucas, K. Curran, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K.

L. Toral-Barza, A. Zask, J. Verheijen, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.

L. Toral-Barza, J. Lucas, M. Young, 2008, Journal of medicinal chemistry.

Novel sesterterpenoid and norsesterterpenoid RCE-protease inhibitors isolated from the marine sponge Hippospongia sp.

David E. Williams, R. Andersen, D. Wojciechowicz, 2002 .

Human Ras converting enzyme endoproteolytic specificity at the P2' and P3' positions of K-Ras-derived peptides.

R. Mallon, E. Frommer, A. Aulabaugh, 2003, Biochimica et biophysica acta.

Human ras-converting enzyme (hRCE1) endoproteolytic activity on K-ras-derived peptides.

R. Mallon, E. Frommer, I. Hollander, 2000, Analytical biochemistry.

Plasminogen activators and their potential in therapy.

I. Hollander, 1987, Critical reviews in biotechnology.

Adenomyoepithelioma of the Breast: A Spectrum of Biologic Behavior

A. Patchefsky, H. Cooper, I. Hollander, 1992, The American journal of surgical pathology.

Enzymatic Synthesis of a Sulfur-Analog of Penicillin Using the “cyclase” of Cephalosporium Acremonium

A. Demain, I. Hollander, S. Wolfe, 1984, Bio/Technology.

A pure enzyme catalyzing penicillin biosynthesis.

A. Demain, J. Heim, I. Hollander, 1984, Science.

Liquid secondary ion mass spectrometric analysis of natural and recombinant proteins and monoclonal antibody light chains with molecular weights between 16 000 and 25 000

M. Siegel, I. Hollander, R. Tsao, 1990 .

Abstract 723: Beyond temsirolimus: Discovery of PKI-587 a highly efficacious dual PI3K/mTOR inhibitor

R. Abraham, N. Brooijmans, L. Feldberg, 2010 .

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.

N. Brooijmans, L. Toral-Barza, J. Lucas, 2009, Journal of medicinal chemistry.

Synthesis of phosphatidylinositol 3-kinase (PI3K) inhibitory analogues of the sponge meroterpenoid liphagal.

R. Andersen, L. Feldberg, R. Mallon, 2010, Journal of medicinal chemistry.

Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates.

I. Hollander, A. Kunz, P. Hamann, 2008, Bioconjugate chemistry.

Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.

N. Brooijmans, L. Feldberg, R. Mallon, 2010, Journal of medicinal chemistry.

Liphagal, a Selective inhibitor of PI3 kinase alpha isolated from the sponge akacoralliphaga: structure elucidation and biomimetic synthesis.

Brian O Patrick, Raymond J Andersen, Frederic Marion, 2006, Organic letters.

Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies.

N. Brooijmans, Steven C. Kim, L. Feldberg, 2010, Bioorganic & medicinal chemistry letters.

Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies.

N. Brooijmans, Steven C. Kim, L. Feldberg, 2010, Bioorganic & medicinal chemistry letters.

5-ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-alpha and mTOR for the treatment of breast cancer.

N. Brooijmans, N. Zhang, R. Mallon, 2010, Bioorganic & medicinal chemistry letters.

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.

R. Abraham, N. Brooijmans, L. Feldberg, 2010, Journal of medicinal chemistry.

Matrix-assisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content.

M. Karas, M. Siegel, B. Smith, 1991, Analytical chemistry.

Liphagal, a Selective Inhibitor of PI3 Kinase ά Isolated from the Sponge Aka coralliphaga: Structure Elucidation and Biomimetic Synthesis

M SoestvanR.W., Brian O. Patrick, David E. Williams, 2006 .

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

L. Feldberg, R. Mallon, J. Lucas, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical Antitumor Efficacy of PKI-587 , a Highly Potent Dual PI 3 K / mTOR Kinase Inhibitor

L. Feldberg, R. Mallon, J. Lucas, 2011 .

PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.

L. Feldberg, R. Mallon, J. Lucas, 2010, Bioorganic & medicinal chemistry letters.

Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor

L. Feldberg, R. Mallon, J. Gibbons, 2010, Molecular Cancer Therapeutics.

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).

D. Kitchen, Z. Husain, R. Nilakantan, 1999, Biochemical pharmacology.

Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.

N. Brooijmans, L. Feldberg, R. Mallon, 2011, Bioorganic & medicinal chemistry letters.

Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.

R. Abraham, N. Brooijmans, L. Feldberg, 2010, Bioorganic & medicinal chemistry letters.

Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.

Judy Lucas, Irwin Hollander, Robert Mallon, 2010, Journal of medicinal chemistry.

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

Irwin Hollander, I. Bernstein, H. Tsou, 2002, Bioconjugate chemistry.

An enzyme-linked immunosorbent assay for the Raf/MEK1/MAPK signaling cascade.

D. Wojciechowicz, C. Kohler, L. Feldberg, 2001, Analytical biochemistry.

Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability.

L. Toral-Barza, J. Lucas, K. Curran, 2009, Bioorganic & medicinal chemistry letters.

Biosynthesis of riboflavin: reductase and deaminase of Ashbya gossypii.

G. Brown, I. Hollander, 1979, Biochemical and biophysical research communications.

Biosynthesis of riboflavin: enzymatic conversion of 5-amino-2,4-dioxy-6-ribitylaminopyrimidine to 6,7-dimethyl-8-ribityllumazine.

G. Brown, J. Braman, I. Hollander, 1980, Biochemical and biophysical research communications.

Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.

Joshua Kaplan, Irwin Hollander, Natasja Brooijmans, 2009, Journal of medicinal chemistry.

Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry.

F. Hillenkamp, M. Siegel, K. Tabei, 1997, Analytical chemistry.

R. Abraham, N. Brooijmans, R. Mallon, 2010, Journal of Medicinal Chemistry.

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.

R. Abraham, N. Brooijmans, R. Mallon, 2010, Journal of medicinal chemistry.

Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.

R. Abraham, N. Brooijmans, R. Mallon, 2010, Bioorganic & medicinal chemistry letters.

A directly labeled TR-FRET assay for monitoring phosphoinositide-3-kinase activity.

Steven C. Kim, R. Mallon, Xiaoke Yang, 2006, Combinatorial chemistry & high throughput screening.